Skip to content

A Randomized Controlled Clinical Study for Buyang Huanwu Decoction in Improving Diabetic Peripheral Neuropathy

Clinical Observation and Mechanism Study for Buyang Huanwu Decoction in Improving Diabetic Peripheral Neuropathy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025037
Enrollment
Unknown
Registered
2019-08-08
Start date
2019-08-31
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Peripheral Neuropathy

Interventions

Sponsors

Hospital ( T.C.M ) Affiliated to Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) those meeting the diagnostic criteria for diabetic peripheral neuropathy; (2) those meeting the syndrome differentiation criteria of qi deficiency and blood stasis syndrome; (3) aged between 18 and 75 (including 18 and 75); (4) voluntarily participate in the study and have signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with acute complications of diabetes, such as diabetic ketosis and hyperosmolar coma; (2) the neuropathy caused mental disease and other causes, such as the neck, lumbar spine lesions (nerve root compression, stenosis, neck lumbar degeneration), cerebral infarction and guillain-barre syndrome, new serious disease of heart head blood-vessel, arteriovenous vascular lesions (venous thrombosis, lymphangitis), has a motor neuropathy, alcoholism, drug especially neurotoxic effect caused by chemotherapy drugs poison and renal insufficiency caused by metabolism of nerve injury causes such as history of neuropathy; (3) pregnant or lactating women or women who intend to become pregnant within the next year; (4) those who are known to be allergic to the components of experimental drugs; (5) those who are unable to cooperate and have participated in other clinical trials within 12 weeks prior to or before the trial.

Design outcomes

Secondary

MeasureTime frame
blood routine;liver function;renal function;urine routines;electrocardiogram;electromyography;

Primary

MeasureTime frame
fasting blood-glucose;glycosylated hemoglobin;TCM symptom index;

Countries

China

Contacts

Public ContactWu Lijuan

Hospital ( T.C.M ) Affiliated to Southwest Medical University

drwu_513@163.com+86 15508305366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026